MedTrace Logo

Using Clonidine to Improve Leg Weakness in People With Heart Failure

NCT00858845 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-05-24

Study results available
· View outcomes & findings →

Summary

People with heart failure often have weakness in their leg muscles. This study will determine whether the leg weakness is due to very high adrenaline levels and whether the medication clonidine can improve leg weakness.

Conditions

Interventions

DRUG

Clonidine Patch

A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.

OTHER

Matching Placebo Patch

A matching placebo patch to be worn for a period of 3 months.

Sponsors & Collaborators

Principal Investigators

  • Holly R. Middlekauff, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-03-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858845 on ClinicalTrials.gov